2/12/2026

Janusmed fosterpåverkan

Janusmed fosterpåverkan – kolestyramin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Kolestyramin

Kolestyramin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Alternova. Kolestyramin Alternova Produktresumé. Läkemedelsverket [www]. [updated 2025-07-22, cited 2026-01-30].

  2. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. Academic Press, Elsevier; 2015.

  3. Nangrahary M, Graham DF, Pang J, Barnett W, Watts GF. Familial hypercholesterolaemia in pregnancy: Australian case series and review. Aust N Z J Obstet Gynaecol. 2023;63(3):402-408.

  4. Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol. 1995;102(2):169-70.

  5. West RJ, Lloyd JK. Use of cholestyramine in treatment of children with familial hypercholesterolaemia. Arch Dis Child. 1973;48(5):370-4.

  6. Reprotox. Cholestyramine. Micromedex [www]. [cited 2026-01-09].

  7. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.

  8. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.

  9. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005;129(3):894-901.

  1. Alternova. Kolestyramin Alternova Produktresumé. Läkemedelsverket [www]. [updated 2025-07-22, cited 2026-01-30].
  2. Schaefer C, Peters P, Miller RK. Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment. Academic Press, Elsevier; 2015.
  3. Nangrahary M, Graham DF, Pang J, Barnett W, Watts GF. Familial hypercholesterolaemia in pregnancy: Australian case series and review. Aust N Z J Obstet Gynaecol. 2023;63(3):402-408.
  4. Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol. 1995;102(2):169-70.
  5. West RJ, Lloyd JK. Use of cholestyramine in treatment of children with familial hypercholesterolaemia. Arch Dis Child. 1973;48(5):370-4.
  6. Reprotox. Cholestyramine. Micromedex [www]. [cited 2026-01-09].
  7. Briggs G, Towers CV, Forinash AB. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 12th ed; 2021.
  8. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010;62:1494-503.
  9. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005;129(3):894-901.